Cardinal Health (CAH) 83.59 $CAH
LabCorp Earnings Top, View Up; Covance Integration Goes On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:50PM CDT
Laboratory Corporation of America Holdings (LH) reported a solid quarter with adjusted earnings per share (EPS) of $2.09, up 13.6% from the year-ago quarter.
ABC: 107.29 (-0.71), CAH: 83.59 (-0.09), LH: 126.22 (+4.01), XRAY: 53.54 (+0.96)
Can Cardinal Health's (CAH) Q4 Earnings Pull a Surprise? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 10:10AM CDT
Cardinal Health Inc. (CAH) is slated to report fourth-quarter fiscal 2015 earnings on Jul 30.
CAH: 83.59 (-0.09), CVS: 113.09 (+1.45), AGIO: 109.20 (-2.68), NUVA: 54.41 (+3.94)
SmarTrend Watching for Potential Rebound in Shares of Cardinal Health After 1.20% Loss
Comtex SmarTrend(R) - Mon Jul 27, 5:21PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $82.13 to a high of $83.16. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $83.04 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
Cardinal Health Set to Possibly Rebound After Yesterday's Selloff of 1.20%
Comtex SmarTrend(R) - Mon Jul 27, 5:20PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $82.13 to a high of $83.16. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $83.04 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
New Cardiac Devices Get Investors' Hearts Pumping
at Investor's Business Daily - Fri Jul 24, 2:16PM CDT
A hot new technology. A widespread, deadly disease. A whole lot of money changing hands. That was the story last Wednesday when St. Jude Medical (STJ) agreed to pay $3.4 billion in cash for Thoratec (THOR), developer of an implant called the left...
BSX: 17.38 (-0.13), ABT: 50.96 (+0.02), ABMD: 74.35 (+0.23), MDT: 77.08 (-0.39), CAH: 83.59 (-0.09), LMAT: 12.15 (+0.91), EW: 151.80 (-4.00), STJ: 74.00 (-0.19), THOR: 62.99 (-0.11), VASC: 36.90 (-0.93), HTWR: 82.27 (+1.38), MMSI: 25.24 (-0.40)
C.R. Bard (BCR) Beats Q2 Earnings & Revenues, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 9:35AM CDT
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.27 in the second quarter of 2015, which exceeded the Zacks Consensus Estimate by a dime.
ABC: 107.29 (-0.71), BCR: 193.73 (+0.78), CAH: 83.59 (-0.09), XRAY: 53.54 (+0.96)
Cardinal Health Announces Three Community Pharmacy Best Practice Winners Who Set the Standard for Innovation
PR Newswire - Fri Jul 24, 8:00AM CDT
During Cardinal Health's annual Retail Business Conference (RBC), one of the nation's largest gatherings of independent pharmacists, three innovative community pharmacies were named as winners of Cardinal Health's prestigious, annual Independent Pharmacy Best Practices.
CAH: 83.59 (-0.09)
Cardinal Health Falls 2.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 23, 4:18PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $84.04 to a high of $87.09. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $85.73 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
After Yesterday's Decline of 2.95%, Cardinal Health Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 23, 4:17PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $84.04 to a high of $87.09. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $85.73 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
The Zacks Analyst Blog Highlights: Marathon Petroleum, GameStop, Tesoro, Lam Research and Cardinal Health - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Marathon Petroleum, GameStop, Tesoro, Lam Research and Cardinal Health
LRCX: 76.85 (-0.90), TSO: 97.11 (-0.67), MPC: 54.76 (+0.25), CAH: 83.59 (-0.09), GME: 45.72 (+0.44)
5 Best Bargain S&P Stocks to Buy Now - Analyst Blog
Sweta Killa - Zacks Investment Research - Wed Jul 22, 9:37AM CDT
With the end of the Greek deal impasse and the China meltdown, the S&P 500 index is only few percentage points away from its all-time high.
MPC: 54.76 (+0.25), LRCX: 76.85 (-0.90), TSO: 97.11 (-0.67), GME: 45.72 (+0.44), CAH: 83.59 (-0.09)
'Women in Pharmacy' Program to Educate and Guide Entrepreneurial Pharmacists
PR Newswire - Wed Jul 22, 8:00AM CDT
In support of its Women in Pharmacy program to help women pharmacists become successful independent pharmacy owners, Cardinal Health will host its fourth annual Pharmacy Ownership Boot Camp on Saturday, July 25, during the company's Retail Business Conference (RBC) in Las Vegas.
CAH: 83.59 (-0.09)
Cardinal Health Helps Position Independent Pharmacists to Win at 25th Annual Retail Business Conference
PR Newswire - Mon Jul 20, 8:00AM CDT
Coming from as far as China and Australia, more than 8,000 attendees will participate in Cardinal Health's annual Retail Business Conference (RBC) at the Venetian Hotel & Convention Center in Las Vegas from July 22-25, 2015. This year marks the 25th anniversary of the conference, which will celebrate the progress independent pharmacists have made in the last quarter of a century. Attendees will network with pharmacy owners from across the country and discover ways to be better 'positioned to win' in today's ever-changing health care environment.
CAH: 83.59 (-0.09)
Global Nuclear Medicine Market Analysis & Forecasts 2015-2020
M2 - Fri Jul 17, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdlprp/nuclear_medicine) has announced the addition of the "Nuclear Medicine Global Market Analysis - Forecast (2014-2020)" report to their offering. This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. This report analyzes the global markets for Nuclear Medicine. The report provides the standard and the tailored research methodology approach. Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. This report provides: - Market forecasts for a minimum of 5 years of all the mentioned segments, sub segments and the regional markets - Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Regional and country level market analysis - Competitive landscaping mapping the key common trends - Company profiling covering the financials, recent activities and the future strategies - Supply chain trends mapping the recent advancements - Market share assessments of the top players along with strategic recommendations for the new entrants Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Nuclear Medicine Global Market, by Isotope 6 Nuclear Medicine Global Market, by End-User 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Cardinal Health Inc - GE Healthcare - IBA Group - Lantheus Medical Imaging Inc - Mallinckrodt Plc - Nordion Inc For more information visit http://www.researchandmarkets.com/research/jd...r_medicine
CAH: 83.59 (-0.09)
Global - Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Analysis To 2020
M2 - Wed Jul 15, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c44pfp/global_biopsy) has announced the addition of the "Global - Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Analysis To 2020" report to their offering. This report titled Global - Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Analysis To 2020 is a 223 page report with 61 Figures and 10 Tables. This report studies in detail the Global Biopsy Device Market, Biopsy Procedure Volume, Products Segment Market for Biopsy Devices, Country Wise Biopsy Device Market and Biopsy Procedure Volume, Companies Biopsy Products Analysis, Major deals in Biopsy Device Market, Driving Factors and Challenges for Biopsy Device Market. Biopsy devices are gaining traction within the industry as a viable alternative to traditional screening methods for cancer. The biopsy device market will experience considerable growth over the forecast period, driven by an increasing number of biopsy procedures. The global biopsy devices market is likely to witness immense demand for screening equipment as doctors conduct ever-increasing numbers of biopsies, while concern for patient comfort will inspire less invasive screening technologies. An increasing prevalence of cancer, geriatric population and increasing demand for minimally invasive procedures are expected to drive market growth during the forecast period. Growing patient awareness levels and the advancement in biopsy techniques are also expected to fuel future growth of the market. Global - Biopsy Device Market Product Segment Analysis: The market for biopsy guidance systems held the largest share in 2014 and is expected to continue to lead the market throughout the forecasting period. The biopsy guidance systems is followed by the needle based biopsy guns segment. Vacuum-assisted biopsy devices represent the fastest growing segment, and increased Medicare reimbursement given for such procedures is expected to help fuel demand. The market for biopsy needles is expected to remain relatively constant throughout the forecasting period. Forceps and Other devices are expected to account for lesser shares as compared to the other segments, due to their specific applications and also risks associated with their use. Global - Biopsy Device Market Country Wise Analysis: United States is the largest regional market for biopsy devices. United States is likely to remain the leading country in biopsy device market throughout the forecasting period. China is the second leading market for biopsy devices being followed by India. Brazil is the fourth most popular country for biopsy devices in 2014. Among the European countries, Germany is the leading market for Biopsy device in 2014. Global - Biopsy Procedure Volume Analysis: In the Global biopsy procedure volume, Asia accounted for the largest share in 2014. It is predicted that Asia will remain at the dominating position in Global biopsy procedures throughout the forecasting period. United States holds the second largest volume share in 2014. Europe is the third leading region for biopsy procedure being followed by Brazil. Global - Company Wise Biopsy Products Analysis: In this segment company wise detailed analysis of biopsy products have been covered along with features and advantages of biopsy products. The report also studies major mergers and acquisition/deals in the biopsy market landscape. The 5 Biopsy Device Segments Market covered in the report are: 1. Needle-based Biopsy Guns (2012 - 2020) 2. Biopsy Needles (2012 - 2020) 3. Biopsy Forceps (2012 - 2020) 4. Biopsy Guidance Systems (2012 - 2020) 5. Others (2012 - 2020) The 12 Companies Biopsy Products analyzed in the Report are 1. Argon Medical Devices 2. Boston Scientific 3. Carefusion Corporation (Acquired By Becton, Dickinson and Company) 4. C. R. BARD, Inc 5. Cardinal Health Inc 6. Cook Medical 7. Devicor Medical Products Inc. 8. Gallini Medical Devices 9. Hologic, Inc 10. INRAD, Inc 11. Intact Medical Corporation 12. TSK Laboratory The 4 Regional Biopsy Procedure Volume covered in the report are: 1. United States (2012 - 2020) 2. Asia (2012 - 2020) 3. Europe (2012 - 2020) 4. Brazil (2012 - 2020) For more information visit http://www.researchandmarkets.com/research/c4...bal_biopsy
BSX: 17.38 (-0.13), CAH: 83.59 (-0.09), HOLX: 37.75 (+0.21)
Nuclear Medicine/Radiopharmaceuticals Market 2015 - Global Forecasts to 2020 for the $6.96 Billion Industry
M2 - Wed Jul 15, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mclbfw/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020" report to their offering. The global radiopharmaceuticals market is expected to reach $6.96 Billion by 2020 from $4.50 Billion in 2015, growing at a CAGR of 9.1% from 2015 to 2020. Nuclear medicine/radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The radiopharmaceuticals market is bifurcated into diagnostics and therapeutics segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET; whereas, radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters. The global radiopharmaceuticals market is segmented on the basis of type, application, and region. Based on type, the nuclear medicine market is categorized into diagnostics and therapeutics segments. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. The diagnostics segment is further segmented into SPECT and PET. In 2014, the SPECT segment accounted for the largest share of the radiopharmaceuticals diagnostics market. The therapeutics segment is further segmented into beta emitters, alpha emitters, and brachytherapy isotopes. In 2014, the beta emitters segment accounted for the largest share of the radiopharmaceuticals therapeutics market. Based on applications, the nuclear medicine market is segmented into diagnostics (SPECT and PET) and therapeutics applications. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. Factors such as advances in radiotracers, alpha radio immunotherapy-based targeted cancer treatment, and increasing number of patients with cancer and cardiovascular aliments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, high demand from emerging countries, and advances in neurological applications are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, stringent regulatory guidelines, and competition from conventional diagnostic procedures are hindering the growth of this market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Global Nuclear Medicine/Radiopharmaceuticals Market, By Type 7 Global Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume 8 Global Nuclear Medicine/Radiopharmaceuticals Market, By Application 9 Global Nuclear Medicine/Radiopharmaceuticals Market, By Region 10 Competitive Landscape 11 Company Profiles - Advanced Accelerator Applications S.A. - Bayer Healthcare - Bracco Imaging - Cardinal Health, Inc. - Eczacibasi-Monrol Nuclear Products - Ge Healthcare - IBA Molecular Imaging - Lantheus Medical Imaging - Mallinckrodt Plc - Nordion, Inc. For more information visit http://www.researchandmarkets.com/research/mclbfw/nuclear
CAH: 83.59 (-0.09)
J&J Beats on Q2 Earnings, Raises 2015 Earnings Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 14, 9:55AM CDT
Johnson & Johnson (JNJ) topped second quarter earnings and revenue estimates; raised earnings outlook for 2015.
JNJ: 99.83 (+0.81), CAH: 83.59 (-0.09), MRK: 58.67 (+1.15), SNY: 53.87 (+0.06)
Downgrade Alert for Cardinal Health (CAH)
Comtex SmarTrend(R) - Tue Jul 14, 7:15AM CDT
Cardinal Health (NYSE:CAH) was downgraded from Buy to Hold at Evercore ISI today. The stock closed yesterday at $86.12 on volume of 1.4 million shares, below average daily volume of 2.6 million. Cardinal Health has overhead space with shares priced $86.12, or 11.4% below the average consensus analyst price target of $97.18. The stock should find resistance at its 50-day moving average (MA) of $87.08, as well as support at its 200-day MA of $84.24.
CAH: 83.59 (-0.09)
Cardinal Health Drives IT Service Delivery Performance with Numerify
PR Newswire - Tue Jul 14, 7:00AM CDT
Numerify, a provider of cloud-based analytics solutions for the business of IT, today announced that Cardinal Health, Inc. (NYSE: CAH), a Fortune 50 healthcare services company, has chosen Numerify's pre-built analytic applications to gain more visibility into their IT service management performance and drive improvements.
CAH: 83.59 (-0.09)
Henry Schein (HSIC) Enters Animal Health Market in Romania - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 13, 1:25PM CDT
Henry Schein, Inc. (HSIC), has forayed into the Romania animal health market with its latest 50% ownership investment in Maravet.
ALGN: 62.02 (+0.82), CAH: 83.59 (-0.09), HSIC: 147.03 (-2.59), XRAY: 53.54 (+0.96)
LabCorp Earnings Top, View Up; Covance Integration Goes On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:50PM CDT
Laboratory Corporation of America Holdings (LH) reported a solid quarter with adjusted earnings per share (EPS) of $2.09, up 13.6% from the year-ago quarter.
ABC: 107.29 (-0.71), CAH: 83.59 (-0.09), LH: 126.22 (+4.01), XRAY: 53.54 (+0.96)
Can Cardinal Health's (CAH) Q4 Earnings Pull a Surprise? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 10:10AM CDT
Cardinal Health Inc. (CAH) is slated to report fourth-quarter fiscal 2015 earnings on Jul 30.
CAH: 83.59 (-0.09), CVS: 113.09 (+1.45), AGIO: 109.20 (-2.68), NUVA: 54.41 (+3.94)
SmarTrend Watching for Potential Rebound in Shares of Cardinal Health After 1.20% Loss
Comtex SmarTrend(R) - Mon Jul 27, 5:21PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $82.13 to a high of $83.16. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $83.04 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
Cardinal Health Set to Possibly Rebound After Yesterday's Selloff of 1.20%
Comtex SmarTrend(R) - Mon Jul 27, 5:20PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $82.13 to a high of $83.16. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $83.04 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
New Cardiac Devices Get Investors' Hearts Pumping
at Investor's Business Daily - Fri Jul 24, 2:16PM CDT
A hot new technology. A widespread, deadly disease. A whole lot of money changing hands. That was the story last Wednesday when St. Jude Medical (STJ) agreed to pay $3.4 billion in cash for Thoratec (THOR), developer of an implant called the left...
BSX: 17.38 (-0.13), ABT: 50.96 (+0.02), ABMD: 74.35 (+0.23), MDT: 77.08 (-0.39), CAH: 83.59 (-0.09), LMAT: 12.15 (+0.91), EW: 151.80 (-4.00), STJ: 74.00 (-0.19), THOR: 62.99 (-0.11), VASC: 36.90 (-0.93), HTWR: 82.27 (+1.38), MMSI: 25.24 (-0.40)
C.R. Bard (BCR) Beats Q2 Earnings & Revenues, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 24, 9:35AM CDT
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.27 in the second quarter of 2015, which exceeded the Zacks Consensus Estimate by a dime.
ABC: 107.29 (-0.71), BCR: 193.73 (+0.78), CAH: 83.59 (-0.09), XRAY: 53.54 (+0.96)
Cardinal Health Announces Three Community Pharmacy Best Practice Winners Who Set the Standard for Innovation
PR Newswire - Fri Jul 24, 8:00AM CDT
During Cardinal Health's annual Retail Business Conference (RBC), one of the nation's largest gatherings of independent pharmacists, three innovative community pharmacies were named as winners of Cardinal Health's prestigious, annual Independent Pharmacy Best Practices.
CAH: 83.59 (-0.09)
Cardinal Health Falls 2.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 23, 4:18PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $84.04 to a high of $87.09. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $85.73 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
After Yesterday's Decline of 2.95%, Cardinal Health Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 23, 4:17PM CDT
Cardinal Health (NYSE:CAH) traded in a range yesterday that spanned from a low of $84.04 to a high of $87.09. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $85.73 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CAH: 83.59 (-0.09)
The Zacks Analyst Blog Highlights: Marathon Petroleum, GameStop, Tesoro, Lam Research and Cardinal Health - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:30AM CDT
The Zacks Analyst Blog Highlights: Marathon Petroleum, GameStop, Tesoro, Lam Research and Cardinal Health
LRCX: 76.85 (-0.90), TSO: 97.11 (-0.67), MPC: 54.76 (+0.25), CAH: 83.59 (-0.09), GME: 45.72 (+0.44)
5 Best Bargain S&P Stocks to Buy Now - Analyst Blog
Sweta Killa - Zacks Investment Research - Wed Jul 22, 9:37AM CDT
With the end of the Greek deal impasse and the China meltdown, the S&P 500 index is only few percentage points away from its all-time high.
MPC: 54.76 (+0.25), LRCX: 76.85 (-0.90), TSO: 97.11 (-0.67), GME: 45.72 (+0.44), CAH: 83.59 (-0.09)
'Women in Pharmacy' Program to Educate and Guide Entrepreneurial Pharmacists
PR Newswire - Wed Jul 22, 8:00AM CDT
In support of its Women in Pharmacy program to help women pharmacists become successful independent pharmacy owners, Cardinal Health will host its fourth annual Pharmacy Ownership Boot Camp on Saturday, July 25, during the company's Retail Business Conference (RBC) in Las Vegas.
CAH: 83.59 (-0.09)
Cardinal Health Helps Position Independent Pharmacists to Win at 25th Annual Retail Business Conference
PR Newswire - Mon Jul 20, 8:00AM CDT
Coming from as far as China and Australia, more than 8,000 attendees will participate in Cardinal Health's annual Retail Business Conference (RBC) at the Venetian Hotel & Convention Center in Las Vegas from July 22-25, 2015. This year marks the 25th anniversary of the conference, which will celebrate the progress independent pharmacists have made in the last quarter of a century. Attendees will network with pharmacy owners from across the country and discover ways to be better 'positioned to win' in today's ever-changing health care environment.
CAH: 83.59 (-0.09)
Global Nuclear Medicine Market Analysis & Forecasts 2015-2020
M2 - Fri Jul 17, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdlprp/nuclear_medicine) has announced the addition of the "Nuclear Medicine Global Market Analysis - Forecast (2014-2020)" report to their offering. This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. This report analyzes the global markets for Nuclear Medicine. The report provides the standard and the tailored research methodology approach. Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. This report provides: - Market forecasts for a minimum of 5 years of all the mentioned segments, sub segments and the regional markets - Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Regional and country level market analysis - Competitive landscaping mapping the key common trends - Company profiling covering the financials, recent activities and the future strategies - Supply chain trends mapping the recent advancements - Market share assessments of the top players along with strategic recommendations for the new entrants Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Nuclear Medicine Global Market, by Isotope 6 Nuclear Medicine Global Market, by End-User 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Cardinal Health Inc - GE Healthcare - IBA Group - Lantheus Medical Imaging Inc - Mallinckrodt Plc - Nordion Inc For more information visit http://www.researchandmarkets.com/research/jd...r_medicine
CAH: 83.59 (-0.09)
Global - Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Analysis To 2020
M2 - Wed Jul 15, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c44pfp/global_biopsy) has announced the addition of the "Global - Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Analysis To 2020" report to their offering. This report titled Global - Biopsy Device Market (By Country Wise and Product Segment) and Biopsy Procedure Volume Analysis To 2020 is a 223 page report with 61 Figures and 10 Tables. This report studies in detail the Global Biopsy Device Market, Biopsy Procedure Volume, Products Segment Market for Biopsy Devices, Country Wise Biopsy Device Market and Biopsy Procedure Volume, Companies Biopsy Products Analysis, Major deals in Biopsy Device Market, Driving Factors and Challenges for Biopsy Device Market. Biopsy devices are gaining traction within the industry as a viable alternative to traditional screening methods for cancer. The biopsy device market will experience considerable growth over the forecast period, driven by an increasing number of biopsy procedures. The global biopsy devices market is likely to witness immense demand for screening equipment as doctors conduct ever-increasing numbers of biopsies, while concern for patient comfort will inspire less invasive screening technologies. An increasing prevalence of cancer, geriatric population and increasing demand for minimally invasive procedures are expected to drive market growth during the forecast period. Growing patient awareness levels and the advancement in biopsy techniques are also expected to fuel future growth of the market. Global - Biopsy Device Market Product Segment Analysis: The market for biopsy guidance systems held the largest share in 2014 and is expected to continue to lead the market throughout the forecasting period. The biopsy guidance systems is followed by the needle based biopsy guns segment. Vacuum-assisted biopsy devices represent the fastest growing segment, and increased Medicare reimbursement given for such procedures is expected to help fuel demand. The market for biopsy needles is expected to remain relatively constant throughout the forecasting period. Forceps and Other devices are expected to account for lesser shares as compared to the other segments, due to their specific applications and also risks associated with their use. Global - Biopsy Device Market Country Wise Analysis: United States is the largest regional market for biopsy devices. United States is likely to remain the leading country in biopsy device market throughout the forecasting period. China is the second leading market for biopsy devices being followed by India. Brazil is the fourth most popular country for biopsy devices in 2014. Among the European countries, Germany is the leading market for Biopsy device in 2014. Global - Biopsy Procedure Volume Analysis: In the Global biopsy procedure volume, Asia accounted for the largest share in 2014. It is predicted that Asia will remain at the dominating position in Global biopsy procedures throughout the forecasting period. United States holds the second largest volume share in 2014. Europe is the third leading region for biopsy procedure being followed by Brazil. Global - Company Wise Biopsy Products Analysis: In this segment company wise detailed analysis of biopsy products have been covered along with features and advantages of biopsy products. The report also studies major mergers and acquisition/deals in the biopsy market landscape. The 5 Biopsy Device Segments Market covered in the report are: 1. Needle-based Biopsy Guns (2012 - 2020) 2. Biopsy Needles (2012 - 2020) 3. Biopsy Forceps (2012 - 2020) 4. Biopsy Guidance Systems (2012 - 2020) 5. Others (2012 - 2020) The 12 Companies Biopsy Products analyzed in the Report are 1. Argon Medical Devices 2. Boston Scientific 3. Carefusion Corporation (Acquired By Becton, Dickinson and Company) 4. C. R. BARD, Inc 5. Cardinal Health Inc 6. Cook Medical 7. Devicor Medical Products Inc. 8. Gallini Medical Devices 9. Hologic, Inc 10. INRAD, Inc 11. Intact Medical Corporation 12. TSK Laboratory The 4 Regional Biopsy Procedure Volume covered in the report are: 1. United States (2012 - 2020) 2. Asia (2012 - 2020) 3. Europe (2012 - 2020) 4. Brazil (2012 - 2020) For more information visit http://www.researchandmarkets.com/research/c4...bal_biopsy
BSX: 17.38 (-0.13), CAH: 83.59 (-0.09), HOLX: 37.75 (+0.21)
Nuclear Medicine/Radiopharmaceuticals Market 2015 - Global Forecasts to 2020 for the $6.96 Billion Industry
M2 - Wed Jul 15, 6:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mclbfw/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020" report to their offering. The global radiopharmaceuticals market is expected to reach $6.96 Billion by 2020 from $4.50 Billion in 2015, growing at a CAGR of 9.1% from 2015 to 2020. Nuclear medicine/radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The radiopharmaceuticals market is bifurcated into diagnostics and therapeutics segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET; whereas, radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters. The global radiopharmaceuticals market is segmented on the basis of type, application, and region. Based on type, the nuclear medicine market is categorized into diagnostics and therapeutics segments. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. The diagnostics segment is further segmented into SPECT and PET. In 2014, the SPECT segment accounted for the largest share of the radiopharmaceuticals diagnostics market. The therapeutics segment is further segmented into beta emitters, alpha emitters, and brachytherapy isotopes. In 2014, the beta emitters segment accounted for the largest share of the radiopharmaceuticals therapeutics market. Based on applications, the nuclear medicine market is segmented into diagnostics (SPECT and PET) and therapeutics applications. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. Factors such as advances in radiotracers, alpha radio immunotherapy-based targeted cancer treatment, and increasing number of patients with cancer and cardiovascular aliments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, high demand from emerging countries, and advances in neurological applications are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, stringent regulatory guidelines, and competition from conventional diagnostic procedures are hindering the growth of this market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Global Nuclear Medicine/Radiopharmaceuticals Market, By Type 7 Global Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume 8 Global Nuclear Medicine/Radiopharmaceuticals Market, By Application 9 Global Nuclear Medicine/Radiopharmaceuticals Market, By Region 10 Competitive Landscape 11 Company Profiles - Advanced Accelerator Applications S.A. - Bayer Healthcare - Bracco Imaging - Cardinal Health, Inc. - Eczacibasi-Monrol Nuclear Products - Ge Healthcare - IBA Molecular Imaging - Lantheus Medical Imaging - Mallinckrodt Plc - Nordion, Inc. For more information visit http://www.researchandmarkets.com/research/mclbfw/nuclear
CAH: 83.59 (-0.09)
J&J Beats on Q2 Earnings, Raises 2015 Earnings Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 14, 9:55AM CDT
Johnson & Johnson (JNJ) topped second quarter earnings and revenue estimates; raised earnings outlook for 2015.
JNJ: 99.83 (+0.81), CAH: 83.59 (-0.09), MRK: 58.67 (+1.15), SNY: 53.87 (+0.06)
Downgrade Alert for Cardinal Health (CAH)
Comtex SmarTrend(R) - Tue Jul 14, 7:15AM CDT
Cardinal Health (NYSE:CAH) was downgraded from Buy to Hold at Evercore ISI today. The stock closed yesterday at $86.12 on volume of 1.4 million shares, below average daily volume of 2.6 million. Cardinal Health has overhead space with shares priced $86.12, or 11.4% below the average consensus analyst price target of $97.18. The stock should find resistance at its 50-day moving average (MA) of $87.08, as well as support at its 200-day MA of $84.24.
CAH: 83.59 (-0.09)
Cardinal Health Drives IT Service Delivery Performance with Numerify
PR Newswire - Tue Jul 14, 7:00AM CDT
Numerify, a provider of cloud-based analytics solutions for the business of IT, today announced that Cardinal Health, Inc. (NYSE: CAH), a Fortune 50 healthcare services company, has chosen Numerify's pre-built analytic applications to gain more visibility into their IT service management performance and drive improvements.
CAH: 83.59 (-0.09)
Henry Schein (HSIC) Enters Animal Health Market in Romania - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 13, 1:25PM CDT
Henry Schein, Inc. (HSIC), has forayed into the Romania animal health market with its latest 50% ownership investment in Maravet.
ALGN: 62.02 (+0.82), CAH: 83.59 (-0.09), HSIC: 147.03 (-2.59), XRAY: 53.54 (+0.96)
